아시아태평양의 오피오이드 시장 예측(-2030년) - 지역별 분석 : 제품별, 용도별, 투여 경로별, 유통 채널별

The Asia Pacific opioids market was valued at US$ 2,406.24 million in 2022 and is expected to reach US$ 3,091.77 million by 2030; it is estimated to register a CAGR of 3.2% from 2022 to 2030.

Surging Chronic Pain Incidence Boosts Asia Pacific Opioids Market

Chronic diseases such as cardiovascular disease, cancer, musculoskeletal diseases, and neurovascular diseases critically affect a person's health by lowering immunity. Moreover, many patients suffering from these conditions experiences chronic pain. The diseases mentioned above are most common in adults and the geriatric population. Nevertheless, cases of these diseases are noticeably growing among children as well. Chronic pain is also common among sportspersons, athletes, and individuals living with past injuries. According to a study published in the NCBI (i.e., National Center for Biotechnology Information), 20% of adults suffer from pain worldwide, and 10% are newly diagnosed with chronic pain per year. While pain affects all populations, regardless of sex, race/ethnicity, income, age, or geography, it is not distributed equally across the world. Prescription opioids, including hydrocodone, oxycodone, and morphine, are potent pain-reducing medications that are used to treat pain caused by injuries, surgeries, and health conditions such as cancer and arthritis.

Increased opioid prescribing practices can be attributed to the insurance reimbursement programs that incentivize opioids over alternative pain treatments, cost structures that encourage more efficient care, and evaluations that combine patient satisfaction with effective pain management. Therefore, owing to the advantage of opioids in pain management, the demand is rising among patients with chronic diseases.

Asia Pacific Opioids Market Overview

The growing geriatric population in China suffering from terminal illnesses is estimated to significantly increase the demand for opioids. As per the World Health Organization (WHO), the country has one of the fastest-growing aging populations. Per the same source, 254 million people were aged 60 and above in 2019 and 176 million people were aged 65 and above. Also, ~28% of the population (402 million people) in China is expected to be aged 60 and above by 2040 due to increasing life expectancy and decreasing birth rates. Geriatric populations are more likely to experience chronic health conditions that are associated with pain, such as arthritis, back pain, cancer, etc. In such cases, opioids are used to manage chronic pain in older adults, which significantly influence the growth of the Asia Pacific opioids market in China. In China, the number of new cancer patients suffering from severe pathological pain has significantly increased. As per a study, "Impact of Continuing Medical Education for Physicians on the Quality of Cancer Pain Treatment in China," published in 2020, the government of China encourages the use of opioid analgesics for the treatment of moderate to severe cancer pain, which is widely available in tertiary hospitals and secondary hospitals across the country. As opioids are a major part of a three-step analgesic ladder and are recommended for relieving moderate and severe cancer pain, increasing awareness regarding such medical conditions and associated treatment can improve the treatment plan for cancer pain.

Asia Pacific Opioids Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Opioids Market Segmentation

The Asia Pacific opioids market is categorized into product, application, route of administration, distribution channel, and country.

Based on product, the Asia Pacific opioids market is segmented immediate release short acting opioid and extended release long acting opioid. The immediate release short acting opioid segment held a larger market share in 2022. The immediate release short acting opioid is further sub segmented into oxycodone, hydrocodone, tramadol, codeine, propoxyphene, and others. The extended release long acting opioid is further sub segmented into oxycodone, fentanyl, morphine, methadone, and others.

In terms of application, the Asia Pacific opioids market is categorized into pain management, anesthesia, diarrhea suppression, cough suppression, de-addiction, and others. The pain management segment held the largest market share in 2022.

By route of administration, the Asia Pacific opioids market is segmented into oral, injectable, and transdermal patch. The oral segment held the largest market share in 2022.

By distribution channel, the Asia Pacific opioids market is bifurcated into hospital pharmacies and retail pharmacies. The hospital pharmacies segment held a larger market share in 2022.

By country, the Asia Pacific opioids market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific opioids market share in 2022.

Endo International plc, Mallinckrodt Plc, Neuraxpharm Pharmaceuticals SL, Mayne Pharma Group Ltd, Rusan Pharma Ltd, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the Asia Pacific opioids market.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. Asia Pacific Opioids Market - Key Market Dynamics

• 4.1 Market Drivers
  • 4.1.1 Surging Chronic Pain Incidence
  • 4.1.2 Increasing Geriatric Population
• 4.2 Market Restraints
  • 4.2.1 Increasing Drug Abuse
• 4.3 Market Opportunities
  • 4.3.1 Strategic Initiatives by Market Players
• 4.4 Impact of Drivers and Restraints:

5. Opioids Market - Asia Pacific Analysis

• 5.1 Asia Pacific Opioids Market Overview
• 5.2 Asia Pacific Opioids Market Revenue (US$ Million), 2020-2030
• 5.3 Asia Pacific Opioids Market Forecast Analysis

6. Asia Pacific Opioids Market Analysis - by Product

• 6.1 Immediate Release Short Acting Opioid
  • 6.1.1 Overview
  • 6.1.2 Immediate Release Short Acting Opioid: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    • 6.1.2.1 Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
• 6.2 Extended Release Long-Acting Opioid
  • 6.2.1 Overview
  • 6.2.2 Extended Release Long-Acting Opioid: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    • 6.2.2.1 Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid

7. Asia Pacific Opioids Market Analysis - by Application

• 7.1 Pain Management
  • 7.1.1 Overview
  • 7.1.2 Pain Management: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
• 7.2 Anesthesia
  • 7.2.1 Overview
  • 7.2.2 Anesthesia: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
• 7.3 Diarrhea Suppression
  • 7.3.1 Overview
  • 7.3.2 Diarrhea Suppression: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
• 7.4 Cough Suppression
  • 7.4.1 Overview
  • 7.4.2 Cough Suppression: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
• 7.5 De-Addiction
  • 7.5.1 Overview
  • 7.5.2 De-Addiction: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
• 7.6 Others
  • 7.6.1 Overview
  • 7.6.2 Others: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Opioids Market Analysis - by Route of Administration

• 8.1 Oral
  • 8.1.1 Overview
  • 8.1.2 Oral: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
• 8.2 Injectable
  • 8.2.1 Overview
  • 8.2.2 Injectable: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
• 8.3 Transdermal Patch
  • 8.3.1 Overview
  • 8.3.2 Transdermal Patch: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Opioids Market Analysis - by Distribution Channel

• 9.1 Hospital Pharmacies
  • 9.1.1 Overview
  • 9.1.2 Hospital Pharmacies: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
• 9.2 Retail Pharmacies
  • 9.2.1 Overview
  • 9.2.2 Retail Pharmacies: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Opioids Market - Country Analysis

• 10.1 Asia Pacific
  • 10.1.1 Asia Pacific: Opioids Market Breakdown, by Key Countries, 2022 and 2030 (%)
    • 10.1.1.1 Asia Pacific: Opioids Market - Revenue and Forecast Analysis - by Country
    • 10.1.1.2 China: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.2.1 China: Asia Pacific Opioids Market Breakdown, by Product
      • 10.1.1.2.2 China: Asia Pacific Opioids Market Breakdown, by Immediate Release Short Acting Opioid
      • 10.1.1.2.3 China: Asia Pacific Opioids Market Breakdown, by Extended Release Long-Acting Opioid
      • 10.1.1.2.4 China: Asia Pacific Opioids Market Breakdown, by Application
      • 10.1.1.2.5 China: Asia Pacific Opioids Market Breakdown, by Route of Administration
      • 10.1.1.2.6 China: Asia Pacific Opioids Market Breakdown, by Distribution Channel
    • 10.1.1.3 Japan: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.3.1 Japan: Asia Pacific Opioids Market Breakdown, by Product
      • 10.1.1.3.2 Japan: Asia Pacific Opioids Market Breakdown, by Immediate Release Short Acting Opioid
      • 10.1.1.3.3 Japan: Asia Pacific Opioids Market Breakdown, by Extended Release Long-Acting Opioid
      • 10.1.1.3.4 Japan: Asia Pacific Opioids Market Breakdown, by Application
      • 10.1.1.3.5 Japan: Asia Pacific Opioids Market Breakdown, by Route of Administration
      • 10.1.1.3.6 Japan: Asia Pacific Opioids Market Breakdown, by Distribution Channel
    • 10.1.1.4 India: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.4.1 India: Asia Pacific Opioids Market Breakdown, by Product
      • 10.1.1.4.2 India: Asia Pacific Opioids Market Breakdown, by Immediate Release Short Acting Opioid
      • 10.1.1.4.3 India: Asia Pacific Opioids Market Breakdown, by Extended Release Long-Acting Opioid
      • 10.1.1.4.4 India: Asia Pacific Opioids Market Breakdown, by Application
      • 10.1.1.4.5 India: Asia Pacific Opioids Market Breakdown, by Route of Administration
      • 10.1.1.4.6 India: Asia Pacific Opioids Market Breakdown, by Distribution Channel
    • 10.1.1.5 South Korea: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.5.1 South Korea: Asia Pacific Opioids Market Breakdown, by Product
      • 10.1.1.5.2 South Korea: Asia Pacific Opioids Market Breakdown, by Immediate Release Short Acting Opioid
      • 10.1.1.5.3 South Korea: Asia Pacific Opioids Market Breakdown, by Extended Release Long-Acting Opioid
      • 10.1.1.5.4 South Korea: Asia Pacific Opioids Market Breakdown, by Application
      • 10.1.1.5.5 South Korea: Asia Pacific Opioids Market Breakdown, by Route of Administration
      • 10.1.1.5.6 South Korea: Asia Pacific Opioids Market Breakdown, by Distribution Channel
    • 10.1.1.6 Australia: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.6.1 Australia: Asia Pacific Opioids Market Breakdown, by Product
      • 10.1.1.6.2 Australia: Asia Pacific Opioids Market Breakdown, by Immediate Release Short Acting Opioid
      • 10.1.1.6.3 Australia: Asia Pacific Opioids Market Breakdown, by Extended Release Long-Acting Opioid
      • 10.1.1.6.4 Australia: Asia Pacific Opioids Market Breakdown, by Application
      • 10.1.1.6.5 Australia: Asia Pacific Opioids Market Breakdown, by Route of Administration
      • 10.1.1.6.6 Australia: Asia Pacific Opioids Market Breakdown, by Distribution Channel
    • 10.1.1.7 Rest of Asia Pacific: Asia Pacific Opioids Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.7.1 Rest of Asia Pacific: Asia Pacific Opioids Market Breakdown, by Product
      • 10.1.1.7.2 Rest of Asia Pacific: Asia Pacific Opioids Market Breakdown, by Immediate Release Short Acting Opioid
      • 10.1.1.7.3 Rest of Asia Pacific: Asia Pacific Opioids Market Breakdown, by Extended Release Long-Acting Opioid
      • 10.1.1.7.4 Rest of Asia Pacific: Asia Pacific Opioids Market Breakdown, by Application
      • 10.1.1.7.5 Rest of Asia Pacific: Asia Pacific Opioids Market Breakdown, by Route of Administration
      • 10.1.1.7.6 Rest of Asia Pacific: Asia Pacific Opioids Market Breakdown, by Distribution Channel

11. Industry Landscape

• 11.1 Overview
• 11.2 Growth Strategies in Opioids Market
• 11.3 Organic Growth Strategies
  • 11.3.1 Overview
• 11.4 Inorganic Growth Strategies
  • 11.4.1 Overview

12. Company Profiles

• 12.1 Endo International plc
  • 12.1.1 Key Facts
  • 12.1.2 Business Description
  • 12.1.3 Products and Services
  • 12.1.4 Financial Overview
  • 12.1.5 SWOT Analysis
  • 12.1.6 Key Developments
• 12.2 Mallinckrodt Plc
  • 12.2.1 Key Facts
  • 12.2.2 Business Description
  • 12.2.3 Products and Services
  • 12.2.4 Financial Overview
  • 12.2.5 SWOT Analysis
  • 12.2.6 Key Developments
• 12.3 Neuraxpharm Pharmaceuticals SL
  • 12.3.1 Key Facts
  • 12.3.2 Business Description
  • 12.3.3 Products and Services
  • 12.3.4 Financial Overview
  • 12.3.5 SWOT Analysis
  • 12.3.6 Key Developments
• 12.4 Mayne Pharma Group Ltd
  • 12.4.1 Key Facts
  • 12.4.2 Business Description
  • 12.4.3 Products and Services
  • 12.4.4 Financial Overview
  • 12.4.5 SWOT Analysis
  • 12.4.6 Key Developments
• 12.5 Rusan Pharma Ltd
  • 12.5.1 Key Facts
  • 12.5.2 Business Description
  • 12.5.3 Products and Services
  • 12.5.4 Financial Overview
  • 12.5.5 SWOT Analysis
  • 12.5.6 Key Developments
• 12.6 Teva Pharmaceutical Industries Ltd
  • 12.6.1 Key Facts
  • 12.6.2 Business Description
  • 12.6.3 Products and Services
  • 12.6.4 Financial Overview
  • 12.6.5 SWOT Analysis
  • 12.6.6 Key Developments

13. Appendix

• 13.1 About The Insight Partners
• 13.2 Glossary of Terms